Published in AIDS on September 24, 2004
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother (2006) 3.27
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS (2003) 2.11
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS (2009) 1.32
Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr (2007) 1.28
The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.24
Exploring the impact of chronic tic disorders on youth: results from the Tourette Syndrome Impact Survey. Child Psychiatry Hum Dev (2011) 1.06
Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry (2004) 0.99
Lack of benefit of accumbens/capsular deep brain stimulation in a patient with both tics and obsessive-compulsive disorder. Neurocase (2010) 0.96
Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol (2009) 0.90
Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons. J Med Virol (2006) 0.89
Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. HIV Clin Trials (2005) 0.87
Clinical risk factors for cytomegalovirus retinitis in patients with AIDS. Ophthalmology (2004) 0.85
Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses (2007) 0.83
Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med (2002) 0.83
Behavioral treatment of a child with PANDAS. J Am Acad Child Adolesc Psychiatry (2004) 0.82
Laboratory-based risk factors for cytomegalovirus retinitis. Can J Ophthalmol (2004) 0.82
Impact of the Florida Medicaid prior-authorization program on use of antipsychotics by children under age six. Psychiatr Serv (2012) 0.81
The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients. Molecules (2012) 0.81
Associations between dietary antioxidant intake and oxidative stress in HIV-seropositive and HIV-seronegative men and women. J Acquir Immune Defic Syndr (2002) 0.81
Aberrant T-lymphocyte development and function in mice overexpressing human soluble amyloid precursor protein-α: implications for autism. FASEB J (2011) 0.81
GFAP expression and social deficits in transgenic mice overexpressing human sAPPα. Glia (2013) 0.81
Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disorders. Neuropsychiatry (London) (2012) 0.79
Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary care centre. Can J Infect Dis Med Microbiol (2009) 0.78
Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients. Can J Infect Dis (2003) 0.77
Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodies. Clin Infect Dis (2002) 0.75
VIth International Congress of Neuroimmunology. Edinburgh, Scotland, September 3-7, 2001. J Neuroimmunol (2002) 0.75